Which has better valuation and earnings, ALMR or OABI?

Alamar Biosciences has higher revenue and earnings than OmniAb. Alamar Biosciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alamar Biosciences $100.42M 21.22 -$29.82M -$1.96 N/A OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A

Does the media favor ALMR or OABI?

In the previous week, OmniAb had 6 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for OmniAb and 2 mentions for Alamar Biosciences. OmniAb's average media sentiment score of 0.76 beat Alamar Biosciences' score of 0.62 indicating that OmniAb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or OABI?

In the previous week, OmniAb had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for OmniAb and 6 mentions for Maravai LifeSciences. OmniAb's average media sentiment score of 0.76 beat Maravai LifeSciences' score of 0.45 indicating that OmniAb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, OABI or BLFS?

BioLife Solutions has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A BioLife Solutions $96.21M 18.48 -$4.59M $1.16 31.36

Is OABI or BLFS more profitable?

BioLife Solutions has a net margin of 53.29% compared to OmniAb's net margin of -115.12%. BioLife Solutions' return on equity of 2.70% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% BioLife Solutions 53.29% 2.70% 2.49%

Does the media refer more to OABI or BLFS?

In the previous week, OmniAb had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.01 beat OmniAb's score of 0.76 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, OABI or PSNL?

OmniAb has higher earnings, but lower revenue than Personalis. Personalis is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A Personalis $69.67M 25.66 -$81.27M -$1.09 N/A

Is OABI or PSNL more profitable?

OmniAb has a net margin of -115.12% compared to Personalis' net margin of -153.84%. OmniAb's return on equity of -16.59% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Personalis -153.84% -46.47% -35.30%

Does the media refer more to OABI or PSNL?

In the previous week, Personalis had 1 more articles in the media than OmniAb. MarketBeat recorded 9 mentions for Personalis and 8 mentions for OmniAb. OmniAb's average media sentiment score of 0.76 beat Personalis' score of 0.38 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, OABI or FTRE?

OmniAb has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A Fortrea $2.68B 0.67 -$986.20M -$0.91 N/A

Is OABI or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to OmniAb's net margin of -115.12%. Fortrea's return on equity of 10.72% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Fortrea -3.18% 10.72% 2.17%

Does the media prefer OABI or FTRE?

In the previous week, OmniAb had 3 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for Fortrea. OmniAb's average media sentiment score of 0.76 beat Fortrea's score of 0.66 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

OmniAb (OABI) Competitors

$4.47 -0.14 (-3.04%)

As of 08/28/2026 04:00 PM Eastern

Compare

OABI vs. ALMR, MRVI, BLFS, PSNL, and FTRE

Should you buy OmniAb stock or one of its competitors? OmniAb's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), Personalis (PSNL), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does OmniAb compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and OmniAb (NASDAQ:OABI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

72.1% of OmniAb shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alamar Biosciences currently has a consensus target price of $31.80, suggesting a potential upside of 3.55%. OmniAb has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Given OmniAb's higher probable upside, analysts plainly believe OmniAb is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, OmniAb had 6 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for OmniAb and 2 mentions for Alamar Biosciences. OmniAb's average media sentiment score of 0.76 beat Alamar Biosciences' score of 0.62 indicating that OmniAb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences has higher revenue and earnings than OmniAb. Alamar Biosciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$100.42M	21.22	-$29.82M	-$1.96	N/A
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Alamar Biosciences has a net margin of 0.00% compared to OmniAb's net margin of -115.12%. Alamar Biosciences' return on equity of 0.00% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
OmniAb	-115.12%	-16.59%	-14.82%

Summary

OmniAb beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does OmniAb compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Maravai LifeSciences has a net margin of -37.07% compared to OmniAb's net margin of -115.12%. Maravai LifeSciences' return on equity of -15.70% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
OmniAb	-115.12%	-16.59%	-14.82%

In the previous week, OmniAb had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for OmniAb and 6 mentions for Maravai LifeSciences. OmniAb's average media sentiment score of 0.76 beat Maravai LifeSciences' score of 0.45 indicating that OmniAb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Maravai LifeSciences presently has a consensus target price of $6.25, indicating a potential downside of 18.62%. OmniAb has a consensus target price of $11.00, indicating a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

OmniAb has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$208.78M	9.55	-$130.77M	-$0.52	N/A
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Summary

OmniAb beats Maravai LifeSciences on 10 of the 15 factors compared between the two stocks.

How does OmniAb compare to BioLife Solutions?

OmniAb (NASDAQ:OABI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

OmniAb currently has a consensus target price of $11.00, suggesting a potential upside of 146.09%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 13.76%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OmniAb has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

BioLife Solutions has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
BioLife Solutions	$96.21M	18.48	-$4.59M	$1.16	31.36

In the previous week, OmniAb had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.01 beat OmniAb's score of 0.76 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to OmniAb's net margin of -115.12%. BioLife Solutions' return on equity of 2.70% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
BioLife Solutions	53.29%	2.70%	2.49%

Summary

BioLife Solutions beats OmniAb on 11 of the 17 factors compared between the two stocks.

How does OmniAb compare to Personalis?

OmniAb (NASDAQ:OABI) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Personalis had 1 more articles in the media than OmniAb. MarketBeat recorded 9 mentions for Personalis and 8 mentions for OmniAb. OmniAb's average media sentiment score of 0.76 beat Personalis' score of 0.38 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

OmniAb presently has a consensus price target of $11.00, indicating a potential upside of 146.09%. Personalis has a consensus price target of $14.54, indicating a potential downside of 14.85%. Given OmniAb's stronger consensus rating and higher probable upside, analysts clearly believe OmniAb is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

OmniAb has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Personalis has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

72.1% of OmniAb shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

OmniAb has a net margin of -115.12% compared to Personalis' net margin of -153.84%. OmniAb's return on equity of -16.59% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Personalis	-153.84%	-46.47%	-35.30%

OmniAb has higher earnings, but lower revenue than Personalis. Personalis is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
Personalis	$69.67M	25.66	-$81.27M	-$1.09	N/A

Summary

OmniAb beats Personalis on 12 of the 16 factors compared between the two stocks.

How does OmniAb compare to Fortrea?

OmniAb (NASDAQ:OABI) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

72.1% of OmniAb shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OmniAb has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

In the previous week, OmniAb had 3 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for Fortrea. OmniAb's average media sentiment score of 0.76 beat Fortrea's score of 0.66 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

OmniAb currently has a consensus price target of $11.00, suggesting a potential upside of 146.09%. Fortrea has a consensus price target of $20.75, suggesting a potential upside of 10.31%. Given OmniAb's higher probable upside, equities research analysts plainly believe OmniAb is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

OmniAb has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
Fortrea	$2.68B	0.67	-$986.20M	-$0.91	N/A

Fortrea has a net margin of -3.18% compared to OmniAb's net margin of -115.12%. Fortrea's return on equity of 10.72% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Fortrea	-3.18%	10.72%	2.17%

Summary

OmniAb beats Fortrea on 9 of the 15 factors compared between the two stocks.

Get OmniAb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OABI vs. The Competition

Export

Metric	OmniAb	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$647.18M	$10.11B	$7.20B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	-12.42	62.76	273.16	25.45
Price / Sales	34.66	111.63	605.01	76.63
Price / Cash	N/A	26.70	76.74	53.00
Price / Book	2.48	37.29	12.98	6.14
Net Income	-$64.78M	$56.67B	$3.48B	$348.86M
7 Day Performance	3.23%	-1.52%	0.13%	-0.80%
1 Month Performance	124.62%	7.21%	7.08%	4.13%
1 Year Performance	179.38%	24.31%	24.67%	15.17%

OmniAb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OABI OmniAb	2.4997 of 5 stars	$4.47 -3.0%	$11.00 +146.1%	+179.4%	$647.18M	$18.67M	N/A	7
ALMR Alamar Biosciences	1.8223 of 5 stars	$33.02 +1.0%	$31.80 -3.7%	N/A	$2.27B	$74.21M	N/A	222
MRVI Maravai LifeSciences	1.3175 of 5 stars	$9.00 +6.8%	$6.25 -30.6%	+217.4%	$2.19B	$185.74M	N/A	610	News Coverage Analyst Forecast Gap Down
BLFS BioLife Solutions	2.9162 of 5 stars	$37.22 +0.1%	$31.38 -15.7%	+45.2%	$1.82B	$96.21M	32.09	440	Positive News High Trading Volume
PSNL Personalis	1.5804 of 5 stars	$17.25 +1.1%	$14.54 -15.7%	+249.1%	$1.79B	$69.65M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OABI) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OmniAb (OABI) Competitors

OABI vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does OmniAb compare to Alamar Biosciences?

Summary

How does OmniAb compare to Maravai LifeSciences?

Summary

How does OmniAb compare to BioLife Solutions?

Summary

How does OmniAb compare to Personalis?

Summary

How does OmniAb compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OmniAb (OABI) Competitors

OABI vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does OmniAb compare to Alamar Biosciences?

Do insiders and institutionals hold more shares of ALMR or OABI?

Do analysts recommend ALMR or OABI?

Does the media favor ALMR or OABI?

Which has better valuation and earnings, ALMR or OABI?

Is ALMR or OABI more profitable?

Summary

How does OmniAb compare to Maravai LifeSciences?

Is MRVI or OABI more profitable?

Does the media refer more to MRVI or OABI?

Do institutionals and insiders believe in MRVI or OABI?

Do analysts prefer MRVI or OABI?

Which has more volatility and risk, MRVI or OABI?

Which has preferable valuation and earnings, MRVI or OABI?

Summary

How does OmniAb compare to BioLife Solutions?

Do analysts prefer OABI or BLFS?

Do institutionals and insiders have more ownership in OABI or BLFS?

Which has more risk & volatility, OABI or BLFS?

Which has stronger earnings & valuation, OABI or BLFS?

Does the media refer more to OABI or BLFS?

Is OABI or BLFS more profitable?

Summary

How does OmniAb compare to Personalis?

Does the media refer more to OABI or PSNL?

Do analysts prefer OABI or PSNL?

Which has more volatility and risk, OABI or PSNL?

Do insiders & institutionals hold more shares of OABI or PSNL?

Is OABI or PSNL more profitable?

Which has stronger valuation & earnings, OABI or PSNL?

Summary

How does OmniAb compare to Fortrea?

Do insiders & institutionals have more ownership in OABI or FTRE?

Which has more volatility & risk, OABI or FTRE?

Does the media prefer OABI or FTRE?

Do analysts rate OABI or FTRE?

Which has better earnings & valuation, OABI or FTRE?

Is OABI or FTRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools